Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Pulmonary Medicine, de Boelelaan 1117, Amsterdam, the Netherlands; Amsterdam Cardiovascular Sciences, Pulmonary Hypertension and Thrombosis, Amsterdam, the Netherlands.
Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Pulmonary Medicine, de Boelelaan 1117, Amsterdam, the Netherlands.
J Heart Lung Transplant. 2022 Aug;41(8):1075-1085. doi: 10.1016/j.healun.2022.05.007. Epub 2022 May 20.
The idiopathic pulmonary arterial hypertension (iPAH) phenotype is changing from a predominantly young female patient to an older, frequently obese patient of either sex. Many newly diagnosed iPAH-patients have risk factors for left ventricular diastolic dysfunction (LVDD), possibly affecting management and treatment.
To determine whether the HFPEF-score identifies a subgroup of iPAH-patients with blunted response to PAH-targeted treatment.
We performed a retrospective analysis of 253 treatment-naïve iPAH-patients (1989-2019) with a confirmed diagnosis after right heart catheterization by a multidisciplinary team. Follow-up RHC measurements were available in 150 iPAH-patients. iPAH-patients were stratified by the HFPEF-score; a score ≥5 identified a higher possibility of (concealed) LVDD.
The presence of a high HFPEF-score in incident iPAH-patients rose 30% in thirty years. Patients with a HFPEF-score ≥5 were older, more often male and/or obese, and had more comorbidities than patients with a HFPEF-score ≤1. A high HFPEF-score was associated with worse survival and poor functional capacity. Right ventricular function was equally depressed among iPAH-groups. Imaging and invasive hemodynamic measurements suggested concealed LVDD in iPAH patients with a high HFPEF-score. At follow-up, hemodynamic and functional responses were similar in iPAH-patients with a high or low HFPEF-score.
While a high HFPEF-score in iPAH is associated with a worse prognosis and signs of LVDD, hemodynamic and functional responses to PAH treatment are not predicted by the HFPEF-score.
特发性肺动脉高压(iPAH)的表型正从以年轻女性为主转变为年龄更大、更常肥胖的男女患者。许多新诊断的 iPAH 患者存在左心室舒张功能障碍(LVDD)的风险因素,这可能会影响管理和治疗。
确定 HFPEF 评分是否能识别对肺动脉高压靶向治疗反应迟钝的 iPAH 患者亚组。
我们对 253 名未经治疗的 iPAH 患者(1989-2019 年)进行了回顾性分析,这些患者在多学科团队进行右心导管检查后被确诊。在 150 名 iPAH 患者中可获得随访 RHC 测量值。iPAH 患者根据 HFPEF 评分进行分层;评分≥5 表明存在更高可能性(隐匿性)LVDD。
新诊断的 iPAH 患者中存在高 HFPEF 评分的比例在三十年内上升了 30%。HFPEF 评分≥5 的患者年龄更大,更常为男性和/或肥胖,且合并症更多,与 HFPEF 评分≤1 的患者相比。高 HFPEF 评分与较差的生存和较差的功能能力相关。iPAH 组的右心室功能同样受到抑制。影像学和有创血流动力学测量表明,HFPEF 评分高的 iPAH 患者存在隐匿性 LVDD。在随访时,HFPEF 评分高或低的 iPAH 患者的血流动力学和功能反应相似。
尽管 iPAH 中的高 HFPEF 评分与预后较差和 LVDD 迹象相关,但 HFPEF 评分不能预测对肺动脉高压治疗的血流动力学和功能反应。